Safety and Immunogenicity Following Administration of a Live, Attenuated Monovalent 2009 H1N1 Influenza Vaccine to Children and Adults in Two Randomized Controlled Trials

@inproceedings{Mallory2010SafetyAI,
  title={Safety and Immunogenicity Following Administration of a Live, Attenuated Monovalent 2009 H1N1 Influenza Vaccine to Children and Adults in Two Randomized Controlled Trials},
  author={Raburn M Mallory and Elissa Malkin and Christopher Ambrose and Terramika Bellamy and Li Shi and Tingting Yi and Taff Jones and George M. Kemble and Filip Dubovsky},
  booktitle={PloS one},
  year={2010}
}
BACKGROUND The safety, tolerability, and immunogenicity of a monovalent intranasal 2009 A/H1N1 live attenuated influenza vaccine (LAIV) were evaluated in children and adults. METHODS/PRINCIPAL FINDINGS Two randomized, double-blind, placebo-controlled studies were completed in children (2-17 y) and adults (18-49 y). Subjects were assigned 4:1 to receive 2 doses of H1N1 LAIV or placebo 28 days apart. The primary safety endpoint was fever ≥38.3°C during days 1-8 after the first dose; the primary… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.
19 Citations
4 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

Similar Papers

Loading similar papers…